News & Events
In the news
Whitepaper – March 2026
Oncolytic Viruses: From Scientific Breakthrough to Manufacturing Reality - by Thibaud DAUPHIN
Oncolytic viruses (OV) represent a transformative class of cancer therapeutics designed to selectively infect, replicate within, and destroy malignant cells while stimulating systemic antitumor immunity. Advances in genetic engineering have further enhanced the antitumor potential of OV by enabling the delivery of therapeutic payloads, improving tumor cell selectivity, and even evading neutralization by the host immune system.
Press Release – SGS x Naobios – March 2026
Naobios and SGS partner to manufacture Respiratory Syncytial Virus (RSV) challenge agent
Collaboration supports Controlled Human Infection Model (CHIM) studies that help accelerate development of effective and affordable RSV vaccines
Naobios at the World Vaccine Congress Europe 2025 – Amsterdam
Discover Gaëtan Blaize's interview
Naobios was proud to participate in the World Vaccine Congress Europe 2025 in Amsterdam, connecting with the global vaccine community and showcasing our expertise in viral product development, GMP manufacturing, and process optimization.
Press Release – TMiMS – October 2025
Naobios and Tokyo Metropolitan Institute of Medical Science partner to develop new live-attenuated vaccine against mpox
Partnership aims to commercialize new mpox vaccine - with higher level of safety - by 2027
Press Release – Olon France – October 2025
Naobios and Olon France partner to deliver process-specific HCP ELISA for an international academic institute
Two France BioLead members collaborate to provide cutting-edge analytical expertise and ensure reliable supply of process-specific HCP ELISA kits for an international vaccine project.
Press Release – Inno4Vac – September 2025
Naobios, Nuvonis and European Vaccine Initiative collaborate on manufacturing influenza challenge agent
Working with the Inno4Vac consortium coordinated by European Vaccine Initiative, Naobios will leverage Nuvonis’s Vero Cell Bank to support development of a controlled human infection model based on influenza virus A(H3N2)
Journée Nationale de la Bioproduction des Biomédicaments (JNBB) 2025
Participation de Naobios à la JNBB 2025
La Journée Nationale de la Bioproduction des Biomédicaments (JNBB) revient le 5 juin 2025 pour renforcer l'attractivité du secteur et ses opportunités professionnelles. Fort de l'enthousiasme suscité l'an dernier, Naobios renouvelle sa participation et affirme son engagement en faveur de l'innovation et du développement de la bioproduction.
Clean Mails – March 2025
How Controlled Human Infection Model (CHIM) Studies will shape the future of vaccine development
Gain insights into how Controlled Human Infection Model studies are transforming vaccine research. Learn about Naobios’ specialized expertise in GMP-certified viral challenge agent manufacturing, enhancing the efficiency and precision of clinical studies.